- Home
- ESPR vs BEAG Comparison
ESPR vs BEAG Comparison
Compare ESPR & BEAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- BEAG
- Stock Information
- Founded
- ESPR 2008
- BEAG 2021
- Country
- ESPR United States
- BEAG United States
- Employees
- ESPR N/A
- BEAG N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- BEAG
- Sector
- ESPR Health Care
- BEAG
- Exchange
- ESPR Nasdaq
- BEAG NYSE
- Market Cap
- ESPR 305.0M
- BEAG 317.4M
- IPO Year
- ESPR 2013
- BEAG 2024
- Fundamental
- Price
- ESPR $0.89
- BEAG $10.40
- Analyst Decision
- ESPR Buy
- BEAG
- Analyst Count
- ESPR 7
- BEAG 0
- Target Price
- ESPR $5.93
- BEAG N/A
- AVG Volume (30 Days)
- ESPR 5.7M
- BEAG 165.1K
- Earning Date
- ESPR 05-06-2025
- BEAG 01-01-0001
- Dividend Yield
- ESPR N/A
- BEAG N/A
- EPS Growth
- ESPR N/A
- BEAG 144.20
- EPS
- ESPR N/A
- BEAG 0.21
- Revenue
- ESPR $259,574,000.00
- BEAG N/A
- Revenue This Year
- ESPR $5.70
- BEAG N/A
- Revenue Next Year
- ESPR N/A
- BEAG N/A
- P/E Ratio
- ESPR N/A
- BEAG $49.81
- Revenue Growth
- ESPR 12.99
- BEAG N/A
- 52 Week Low
- ESPR $0.82
- BEAG $9.84
- 52 Week High
- ESPR $3.94
- BEAG $11.20
- Technical
- Relative Strength Index (RSI)
- ESPR 36.95
- BEAG N/A
- Support Level
- ESPR $0.93
- BEAG N/A
- Resistance Level
- ESPR $1.11
- BEAG N/A
- Average True Range (ATR)
- ESPR 0.10
- BEAG 0.00
- MACD
- ESPR 0.02
- BEAG 0.00
- Stochastic Oscillator
- ESPR 25.10
- BEAG 0.00
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About BEAG BOLD EAGLE ACQUISITION CORP
Bold Eagle Acquisition Corp is a blank check company.